PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 5, 2026Cancer Research0 citations

Abstract 4584: Effects of ergosterol peroxide on proteostasis disruption in triple negative breast cancer cells

View Full Paper
MMMichelle MartínezABAliyah L. Bocachica-AdornoAAAdriana Y. Aponte-Ramos

Key Points

  • The study aims to investigate the effects of ergosterol peroxide on cellular processes in triple negative breast cancer cells.
  • Assessed cytotoxicity of ergosterol peroxide in TNBC models SUM149 and MDA-MB-231.
  • Conducted protein synthesis assays after treatment with ergosterol peroxide, vehicle, and cyclophosphamide.
  • Utilized aggresome assays to evaluate protein aggregation in cancer and non-cancerous cells.
  • Performed western blots probing for ubiquitin to assess protein degradation.
  • Ergosterol peroxide exhibited selective cytotoxicity in TNBC cells at low micromolar concentrations.
  • Significantly increased protein aggregation was observed in treated TNBC cells compared to vehicle control.
  • Ergosterol peroxide decreased cancer cell degradation as indicated by reduced levels of ubiquitin after 24 hours.

Abstract

Abstract Triple-negative breast cancer (TNBC) is a highly aggressive and heterogeneous subtype of breast cancer characterized by the absence of estrogen receptor, progesterone receptor, and HER2 expression, known for its high malignancy, invasiveness, and propensity for metastasis. Due to the lack of targeted therapies, TNBC patients typically undergo multimodality chemotherapy with cytotoxic agents like taxanes, anthracyclines, and cyclophosphamide. Therefore, there is an urgent need for selective therapies for TNBC. Natural products have gained significant attention for their potential in cancer therapy, as around 60% of clinically approved anticancer drugs were inspired by secondary metabolites found in nature. In our laboratory, we work with Ergosterol Peroxide (EP), a bioactive compound extracted from the Ganoderma lucidum mushroom. We discovered that the natural product EP exhibits selective cytotoxicity against TNBC models, demonstrating activity in the low micromolar range while sparing normal cells. Our studies indicate that EP exerts its anticancer effects by disrupting critical cellular processes including proteostasis, protein synthesis, and protein degradation pathways. We hypothesize that EP compromises TNBC cell viability by disrupting proteostatic balance. Mechanistically, we propose that EP inhibits protein synthesis and induces mitochondrial dysfunction, which collectively impair the ability of TNBC cells to restore protein homeostasis, ultimately resulting in cell death. To validate our hypothesis, we performed protein synthesis assays in two TNBC cell models, SUM149 and MDA-MB-231. Veh (0.2% DMSO), EP (20μM), or cyclophosphamide (1μM, positive control) were administered for 6 or 24h. EP effects on protein aggregation, under Veh, EP, or MG132 (positive control) in SUM149 or MDA-MB-231 TNBC cells and MCF10A non-cancerous cells, we used an aggresome assay. Finally, to assess protein degradation we performed western blots probing for ubiquitin. We previously established that EP increases ROS levels in TNBC cells. EP affects protein synthesis, compared to negative vehicle control treated cells, and in reduced capacity when compared to cyclophosphamide. Moreover, EP significantly increases protein aggregation, although the signal detected for MG132 was greater. Finally, EP decreases cancer cell degradation, as seen by decreased levels of ubiquitin when treated after 24h. In summary, EP demonstrates the capacity to modulate proteostasis in TNBC cells. Further investigation is warranted to comprehensively characterize the intricate mechanistic pathways by which EP exerts its anticancer effects in this malignancy. Citation Format: Michelle Martínez-Montemayor, Aliyah Bocachica-Adorno, Adriana Aponte-Ramos, Taotao Ling, Fatima Rivas. Effects of ergosterol peroxide on proteostasis disruption in triple negative breast cancer cells abstract. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 4584.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Martínez et al. (2026) studied this question.

synapsesocial.com/papers/69d1fd13a79560c99a0a2db3https://doi.org/10.1158/1538-7445.am2026-4584
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1[Anti-breast cancer effect of a mitochondrion-targeted derivative of ergosterol peroxide in vitro and in vivo].2024
  2. 2[Mechanism of ergosterol peroxide on MCF-7 breast cancer cells based on network pharmacology and in vitro experiments].2024 · 3 citations
  3. 3Abstract C053: Pleurotus ostreatus ethanolic extract suppresses cell proliferation and restores apoptotic and DNA repair pathways in DMBA-NMU-induced breast cancer in female Sprague Dawley rats2025 · 1 citations
  4. 4Abstract 988: Synthesis, characterization, and biological evaluation of polyisoprenylated phosphonyl ester inhibitors on triple-negative breast cancer2026
  5. 5Abstract PS4-07-16: Epigenetic Reactivation of estrogen receptor beta Enhances Antitumor Activity of a Novel estrogen receptor beta agonist CIDD-0149897 in Triple-Negative Breast Cancer2026